Core Viewpoint - The article discusses the performance of deep value fund managers during different market conditions, highlighting their underperformance in the current bull market compared to growth-style fund managers, particularly in sectors like technology and innovation [4][20]. Group 1: Performance Comparison - In the past three years of bear markets, deep value fund managers performed relatively well, with many managing over 10 billion in assets [5]. - As of September 24, 2023, mainstream deep value fund managers like Xu Yan and Jiang Cheng had annual returns below 20%, while the average return of the CSI Active Equity Fund Index reached 34.11% [6][12]. - The article notes that deep value fund managers typically focus on low-valuation, stable companies, which leads to lower returns in bull markets but better performance in bear markets [14][19]. Group 2: Investment Philosophy - Deep value fund managers invest from an owner's perspective, focusing on long-term intrinsic value rather than short-term market fluctuations [16]. - They emphasize "quality and price," seeking high-quality companies that are undervalued due to market sentiment [17]. - Safety margins are crucial in their investment decisions, as they aim to protect against errors and downside risks [17][18]. Group 3: Market Trends and Strategies - The current bull market has favored growth-style funds, particularly those heavily invested in technology, with some achieving over 200% annual returns [7]. - Deep value fund managers often hold significant positions in traditional sectors like finance and real estate, which have underperformed in the current market [14][19]. - The article suggests that deep value funds should be considered for core portfolio allocations, especially for conservative investors [23][24]. Group 4: Selection Criteria - Not all low-valuation stocks represent deep value; some may belong to contrarian or cyclical strategies [29]. - Investors should focus on the stability of deep value fund managers' styles, as many have shifted towards growth or other strategies over time [36][38]. - The article advises that deep value funds can serve as a bottom-layer allocation in a diversified portfolio, balancing risk and return [24][26].

Group 1 - The company, Puluo Pharmaceutical, announced a share buyback of 10.03 million shares, representing 0.87% of its total share capital of approximately 1.158 billion shares, with a total transaction amount of about 144 million yuan [1] - The highest and lowest transaction prices during the buyback were 14.82 yuan and 13.62 yuan per share, respectively [1] - As of the report date, the market capitalization of Puluo Pharmaceutical is 18.9 billion yuan [1] Group 2 - For the first half of 2025, the company's revenue composition shows that the pharmaceutical industry accounts for 99.6%, while other businesses contribute 0.4% [1]

证券代码：000739 证券简称：普洛药业 公告编号：2025-55 普洛药业股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）于2025年2月19日召开第九届 董事会第十次会议审议通过了《关于回购公司股份方案的议案》，同意公司使用 自有资金以集中竞价交易方式回购公司部分股份，用于实施公司股权激励或员工 持股计划。本次回购股份价格不超过人民币22元/股（含），回购资金总额不低 于人民币7,500万元（含）且不超过人民币15,000万元（含）。具体回购股份数 量以回购期限届满或回购股份实施完毕时实际回购股份数量为准。回购期限为自 公司董事会审议通过回购股份方案之日起12个月内。具体内容详见公司分别于 2025 年 2 月 20 日 、 2025 年 2 月 21 日 在 《 证 券 时 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露的《第九届董事会第十次会议决议公告》 （公告编号：2025-04）、《关于回购公司股份方案的公告》（公告编号： ...

本报讯(记者邬霁霞见习记者王楠)9月30日，普洛药业（000739）股份有限公司(以下简称"普洛药业")发 布公告称，近日，公司全资子公司浙江普洛巨泰药业有限公司收到国家药品监督管理局下发的头孢泊肟 酯片《药品补充申请批准通知书》。 目前，该产品已通过仿制药质量和疗效一致性评价，此举有助于拓展产品未来市场空间，提升市场竞争 力，并对普洛药业的经营发展带来积极作用。 公告显示，头孢泊肟酯为口服广谱第三代头孢菌素，在体内经非特异性酯酶水解为头孢泊肟后发挥抗菌 作用，对革兰氏阳性菌及阴性菌均具有一定疗效。其适应症包括敏感菌引起的上呼吸道感染、下呼吸道 感染、单纯性泌尿道感染、单纯性皮肤及皮肤软组织感染、急性单纯性淋球菌性尿道炎和子宫颈炎，以 及由奈瑟氏淋球菌导致的肛周炎等。 截至本公告披露日，普洛药业的头孢泊肟酯片(规格：0.1g)累计研发投入金额为人民币817.68万元。 ...

Group 1 - Yinglian Co., Ltd. expects a net profit increase of 1531.13% to 1672.97% year-on-year for the first three quarters of 2025, with projected revenue of 1.63 billion to 1.65 billion yuan, a growth of 9.49% to 10.83% [1] - Meixin Sheng plans to reduce its shareholding by no more than 1% through centralized bidding and block trading [1] - Huayin Technology signed two sales contracts totaling 402 million yuan, with one contract for special functional materials and another for research project materials [3] Group 2 - Shen Highways reported a total toll revenue of 114 million yuan for August [5] - Dash Smart signed a contract worth 113 million yuan for a smart hospital project [7] - Tianbang Food received an administrative regulatory measure decision from the China Securities Regulatory Commission for failing to disclose information in a timely manner [8] Group 3 - Fashilong plans to invest 250 million yuan to establish a wholly-owned subsidiary focused on AI applications and cloud computing [10] - Junpu Intelligent received a government subsidy of 20 million yuan, accounting for 243.97% of its audited net profit for 2024 [11] - Longyun Co. plans to apply for a bank credit limit of 32 million yuan [12] Group 4 - Yifan Pharmaceutical's subsidiary received acceptance for a drug registration application for a medication used to lower phenylalanine levels in patients [12] - Rundu Co. received a drug registration certificate for a hypertension medication [13] - Huahai Qingke elected a new employee director and appointed a new vice president [17] Group 5 - Wanyi Technology received a government subsidy of 173,000 yuan [19] - Haizheng Pharmaceutical's tacrolimus capsules passed the consistency evaluation for generic drugs [20] - Pulaike's new veterinary vaccine received registration certification [22] Group 6 - Boguang New Materials signed a major sales contract estimated at 4.3 billion to 5 billion yuan for nickel powder products [41] - Electric Soul Network announced plans for shareholders to reduce their holdings by up to 1.63% [42] - Jin Haitong's shareholders plan to reduce their holdings by up to 3% [44]

Core Insights - The article highlights that Puluo Pharmaceutical has been recognized for its significant investment in R&D, being listed among the "Top 500 Private Enterprises in R&D Investment" for two consecutive years [1][2] - The company emphasizes its strategy of "innovation-driven development and talent-led innovation," maintaining a high level of R&D investment and revenue ratio [1] R&D Investment - In the first half of 2025, Puluo Pharmaceutical's R&D investment reached 360 million yuan, representing a year-on-year increase of 14.46% [1] - The R&D expense ratio was 5.95%, an increase of 1.05 percentage points compared to the same period last year [1] Hardware Development - The company is focused on enhancing its global innovative drug R&D and production service platform, which integrates the entire process from drug discovery to commercialization [1] - Puluo Pharmaceutical is optimizing its cutting-edge technology platform in key areas such as fluid chemistry, peptides, synthetic biology, and enzyme catalysis, ensuring robust hardware support for R&D innovation [1] Talent Development - Puluo Pharmaceutical has made significant progress in building a high-end R&D talent team by implementing an international recruitment system and optimizing compensation structures [2] - The company has successfully attracted experienced experts and young talents from renowned pharmaceutical companies and research institutions, forming a specialized R&D team across various disciplines [2] Future Outlook - Puluo Pharmaceutical is committed to its mission of "technology innovation serving health" and plans to continue increasing its R&D investment [2] - The company aims to further optimize its global innovative drug R&D and production service system while deepening talent development and high-end R&D capabilities [2]

格隆汇9月29日丨普洛药业(000739.SZ)公布，全资子公司浙江普洛巨泰药业有限公司收到国家药品监督 管理局下发的头孢泊肟酯片《药品补充申请批准通知书》。头孢泊肟酯为口服广谱第三代头孢菌素，进 入体内后经非特异性酯酶水解为头孢泊肟发挥抗菌作用，对革兰氏阳性菌和阴性菌均有效；适用于敏感 菌引起的上呼吸道感染、下呼吸道感染、单纯性泌尿道感染、单纯性皮肤和皮肤软组织感染、急性单纯 性淋球菌性尿道炎和子宫颈炎、由奈瑟氏淋球菌引起的肛周炎等。 ...

格隆汇9月29日丨普洛药业(000739.SZ)公布，全资子公司浙江普洛巨泰药业有限公司收到国家药品监督 管理局下发的头孢泊肟酯片《药品补充申请批准通知书》。头孢泊肟酯为口服广谱第三代头孢菌素，进 入体内后经非特异性酯酶水解为头孢泊肟发挥抗菌作用，对革兰氏阳性菌和阴性菌均有效；适用于敏感 菌引起的上呼吸道感染、下呼吸道感染、单纯性泌尿道感染、单纯性皮肤和皮肤软组织感染、急性单纯 性淋球菌性尿道炎和子宫颈炎、由奈瑟氏淋球菌引起的肛周炎等。 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-53 普洛药业股份有限公司 关于获得药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）全资子公司浙江普洛巨 泰药业有限公司（于 2025 年 7 月由浙江巨泰药业有限公司更名，以下简称"巨 泰药业"）收到国家药品监督管理局（以下简称"药监局"）下发的头孢泊肟酯 片《药品补充申请批准通知书》。现将有关情况公告如下： 一、药品注册批准情况 1、产品名称：头孢泊肟酯片 2、剂型：片剂 3、规格：0.1g（按 C15H17N5O6S2计） 4、补充申请事项：仿制药质量和疗效一致性评价 5、上市许可持有人：浙江普洛巨泰药业有限公司 6、通知书编号：2025B04244 7、原药品批准文号：国药准字 H20050147 8、审批结论：经审查，本品通过仿制药质量和疗效一致性评价。 四、风险提示 公司一直高度重视药品研发，并非常注重药品研发、制造及销售等环节的质 量、安全和合规。但是药品的生产和销售可能会受到政策法规、市场环境变化等 不确定 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-54 一、担保情况概述 1、2025 年 9 月 8 日，普洛药业股份有限公司（以下简称"公司"）与招商 银行股份有限公司金华义乌支行（"招商银行"）签订《不可撤销担保书》（合 同编号：571HT250904T00053801）,同意为公司全资子公司浙江普洛得邦制药有 限公司（以下简称"得邦制药"）与招商银行签署的《借款合同》（合同编号： 571HT250904T000538）提供流动资金借款 2,000 万元连带责任保证，担保期限为 12 个月。 2、2025 年 9 月 9 日，公司与中国工商银行股份有限公司东阳支行（以下简 称"工商银行"）签订《保证合同》[合同编号：0120800011-2025 年东阳（保） 字 0158 号]，同意为公司全资子公司得邦制药与工商银行签署的《流动资金借款 合同》[合同编号：0120800011-2025 年（东阳）字 02596 号]中的 5,000 万元流 动资金贷款提供连带责任保证，担保期限 12 个月。 3、2025 年 9 月 10 日，公司与中国银行股份有限公司东阳支行（以下简称 "中国银行"） ...